Today’s Trending Biotech Stocks
The fate and fortune of a biotechnology company typically relies on two events, results from clinical trials and FDA approval. Nonetheless, to get the most out of what these explosive stocks could potentially offer would mean knowing when these fundamental events are going to take place.

Returns on investments in a biotech stock can be nothing less than impressive, if a position is taken at the right time. Investors taking positions in a company prior to those catalysts may be gaining an advantage due to upside potential if the drug or treatment gets the green light from the FDA.
Biotech Stocks That Hit Fresh 52-Week Highs on Sept. 4
- Aptinyx Inc (APTX)
- Becton Dickinson and Co (BDX)
- BioCryst Pharmaceuticals, Inc. (BCRX)
- DexCom, Inc. (DXCM)
- EXACT Sciences Corporation (EXAS)
- Genomic Health, Inc. (GHDX)
- Haemonetics Corporation (HAE)
- Inspire Medical Systems Inc (INSP)
- Masimo Corporation (MASI)
- Myriad Genetics, Inc. (MYGN)
- Neurocrine Biosciences, Inc. (NBIX)
- Omeros Corporation (OMER)
- ProQR Therapeutics NV (PRQR)
- Repligen Corporation (RGEN)
- STAAR Surgical Company (STAA)
- Uniqure NV (QURE)
Furthermore, several ETF’s tracking the sector have been on an uptrend, including the Health Care SPDR (XLV), the S&P Biotech ETF (XBI) and Nasdaq iShares Biotechnology Index (IBB). As the biotech sector continues to reach new highs, here are a few biotech stocks that may present early opportunities to investors.

